Atrix/Fujisawa Aczone Acne Therapy Has Mid-2005 Action Date
This article was originally published in The Pink Sheet Daily
Firms submit NDA for topical treatment of acne vulgaris with dapsone 5% gel, currently available as an oral tablet. Aczone (formerly Atrisone) NDA is based on two Phase III trials in 3,000 patients.
You may also be interested in...
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.